Detailed Information on Publication Record
2002
Endothelin-1 gene polymorphism in the identification of patients at risk for malignant ventricular arrhythmia
KOZÁK, Milan, Lydie IZAKOVIČOVÁ HOLLÁ, Lubomír KŘIVAN, Anna VAŠKŮ, Milan SEPŠI et. al.Basic information
Original name
Endothelin-1 gene polymorphism in the identification of patients at risk for malignant ventricular arrhythmia
Authors
KOZÁK, Milan (203 Czech Republic, guarantor), Lydie IZAKOVIČOVÁ HOLLÁ (203 Czech Republic), Lubomír KŘIVAN (203 Czech Republic), Anna VAŠKŮ (203 Czech Republic), Milan SEPŠI (203 Czech Republic), Bořivoj SEMRÁD (203 Czech Republic) and Jiří VÁCHA (203 Czech Republic)
Edition
Medical Science Monitor (International Medical Journal of Experimental and Clinical Research), USA, International Scientific Literature, Inc, 2002, 1234-1010
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30201 Cardiac and Cardiovascular systems
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
RIV identification code
RIV/00216224:14110/02:00007238
Organization unit
Faculty of Medicine
Keywords in English
gene; endothelin; polymorphism; ET-1; arrhythmia; defibrillator
Tags
Změněno: 13/5/2003 15:03, prof. MUDr. Lydie Izakovičová Hollá, Ph.D.
Abstract
V originále
The endothelins are peptides with vasoconstriction and growth-promoting properties. Endothelin-1 (ET-1) is known for its direct positive inotropic and chronotropic effects on isolated heart, and for growth effects. The aim of this pilot study was to investigate the frequency distribution of a common polymorphism of the endothelin gene and its possible relation to the hemodynamic consequences of malignant ventricular arrhythmia in patients with structural heart disease. We studied 26 consecutive patients with malignant ventricular arrhythmia and implantable cardioverter defibrillators (ICD), mean age 62.7 years, mean LVEF 0.37. The Taq polymorphism of ET-1 was detected using our original PCR method. Out of the 26 patients, 9 (34%) had reccurent palpitations and 8 (30.8%) had syncopes during their malignant arrhythmic episodes. 19 of the patients were receiving amiodarone after ICD implantation, 7 were not. 15 patients had the (++) and 11 had (+-) ET-1 genotype, none had the (--) genotype. The risk of syncopes was associated with the (++) genotype (p=0.01). Patients with amiodarone had a significantly higher frequency of the (++) genotype (p=0.011). All our results suggested that the presence of the (++) ET-1 genotype in patients with structural heart disease, severe left ventricular dysfunction, and malignant ventricular arrhythmia put these patients at a higher risk of hemodynamic collapse during arrhythmic episodes.
Links
| MSM 141100002, plan (intention) |
|